1 / 47

seAFOod initiation MEETING

seAFOod initiation MEETING. THE SEAFOOD (SYSTEMATIC EVALUATION OF ASPIRIN AND FISH OIL)POLYP PREVENTION TRIAL. Anna Sandell 19 July 2012. agenda. GENERAL STUDY INFORMATION STUDY OUTLINE AND OBJECTIVES PROTOCOL OUTLINE INVESTIGATIONAL MEDICINAL PRODUCT STUDY SCHEDULED VISITS & PROCEDURES

cassia
Download Presentation

seAFOod initiation MEETING

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. seAFOod initiation MEETING THE SEAFOOD (SYSTEMATIC EVALUATION OF ASPIRIN AND FISH OIL)POLYP PREVENTION TRIAL Anna Sandell 19 July 2012

  2. agenda • GENERAL STUDY INFORMATION • STUDY OUTLINE AND OBJECTIVES • PROTOCOL OUTLINE • INVESTIGATIONAL MEDICINAL PRODUCT • STUDY SCHEDULED VISITS & PROCEDURES • CONSENT & RANDOMISATION • BIOLOGICAL SAMPLES • ADVERSE EVENT REPORTING • PROHIBITED MEDICATIONS • EMERGENCY UNBLINDING • WITHDRAWAL OF PARTICIPANTS • STUDY MANAGEMENT EXPECTATIONS

  3. GENERAL STUDY INFORMATION • CHIEF INVESTIGATOR: Professor Mark Hull, Molecular Gastroenterology, University of Leeds • FUNDER: • Efficacy and Mechanism Evaluation programme (EME) • Very competitive and rigorous process – Approx £1million • SPONSOR: • University of Leeds • CO-ORDINATING CENTRE: • Nottingham Clinical Trials Unit • Anna Sandell Trial Manager • Ellie Harrison Trial Administrator • Statistics • Data Entry • Data Management

  4. STUDY OUTLINE AND OBJECTIVES • OUTLINE: • PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED 2X2 FACTORIAL TRIAL • PRIMARY OBJECTIVE • To determine whether the naturally-occurring omega -3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) prevents colorectal adenomas, either alone or in combination with aspirin • SECONDARY OBJECTIVE • To assess the tolerability and safety of EPA in the free fatty acid form (EPA-FFA) alone, and in combination with aspirin, in elderly (60-75) years participants • 1o endpoint – number of patients with a polyp(s) • 2o endpoints – polyp number, ‘advanced’ lesions, location, AEs

  5. PROTOCOL OUTLINE • INCLUSION: • 60-73 Yrs BCSP Patients • Classified as High Risk at the first complete screening Colonoscopy within past 4 weeks • nb high risk = 5 or more small adenomas or 3 or more adenomas with at least one being ≥10mm diameter

  6. PROTOCOL OUTLINE • EXCLUSION CRITERIA: main ones listed here (see protocol for extensive list) • Need for more than one repeat colonoscopy or flexible sigmoidoscopy within a 3 month window • Malignant change in an adenoma requiring colorectal cancer MDT management • Regular (>3 doses/week) prescribed or OTC aspirin or prescribed or OTC non-aspirin NSAID use – not prepared to stop OTC use • Aspirin intolerance, hypersensitivity including aspirin-sensitive asthma • Active peptic ulcer disease within past 3 months or any previous peptic ulcer (not on PPI treatment) NB if taking PPI then they are eligible • Fish or seafood allergy • Current or planned regular(>3 doses/week) use of fish oil supplements - not prepared to stop OTC use

  7. PROTOCOL OUTLINE cont. • EXCLUSION CRITERIA: main ones listed here (see protocol for extensive list) • Known clinical diagnosis or gene carrier of a hereditary CRC predisposition,(Familial Adenomatous Polyposis) or Hereditary Non Polyposis Colorectal Cancer • Previous or newly diagnosed Inflammatory Bowel Disease or colorectal resection • Known bleeding diathesis or concomitant warfarin therapy or any other anti-coagulant or anti-platelet therapy • Severe liver impairment (anyone who is known to have or is likely to have a coagulopathy (INR>/=1.5) from liver impairment) • Severe renal failure (creatinine clearance <10ml/min) • Current Methotrexate use at a weekly dose of 15 mg or more • Participating in another interventional clinical trial • Failure to give Informed Consent

  8. INVESTIGATIONAL MEDICINAL PRODUCT • GASTRO-RESISTANT EPA-FFA 2G DAILY (taken as 2 x 500mg capsules BD) • ENTERIC-COATED ASPIRIN 300MG DAILY (taken as 1 x 300mg tablet OD) • PLACEBO FOR EPA-FFA (taken as 2 x capsules BD) • PLACEBO FOR ASPIRIN (taken as 1 x tablet OD) • NB all trial medication must be taken with food and everyone is blinded to the treatment allocation • DURATION OF TRIAL MEDICATION: • Start next morning following dispensing of trial medication at v1 • Take every day until day before surveillance colonoscopy • NB If participant has any planned invasive medical procedure then they must stop taken the trial medication for 10 days before the planned procedure and re-start 4 days after the procedure

  9. PHARMACY & DISPENSING • Dispensing is at week 0 and week 25 (visit 4) and week 50 (visit 5a) if required • Each participant has 5 packs of these at each dispensing • (EPA-FFA 500mg or Placebo capsules 150 capsules per container)

  10. PHARMACY & DISPENSING • And 3 packs of these at each dispensing • (Aspirin 300mg E/C or Placebo 62 tablets • per container)

  11. STUDY SCHEDULED VISITS & PROCEDURES • Colonoscopy – up to 4 weeks before V1

  12. STUDY SCHEDULED VISITS & PROCEDURES • V1 (baseline total 1-1.5 hr) • - consent, randomisation, FFQ, blood and urine

  13. CONSENT • 3 OPTIONS: • SSP or Research Nurse takes Informed Consent • SSP or Research Nurse takes Informed Consent but PI counter-signature is required • PI only can take Informed Consent • ALWAYS ENSURE YOU HAVE THE PARTICIPANT’S CONSENT PRIOR • TO ANY STUDY RELATED PROCEDURE • NB - ensure that you find out your Trust requirements prior to recruitment start • - ensure that the PI has delegated the responsibility for Informed Consent to you and this is recorded on the delegation log prior to recruitment start

  14. RANDOMISATION • INSTRUCTIONS ARE AT THE FRONT OF EVERY CASE RECORD FORM • Web-based system • Accessed from any computer with internet access • https://ctu4.nottingham.ac.uk/0921/login.asp • Easy to use • Will provide Participant ID following confirmation of participant details (pt initials, gender, DOB) – use this ID for all study documentation • Will generate prescription – print off, obtain prescriber’s signature, take to pharmacy • Keep your username and password safe for log-in (audit trial) • New members of staff need to request username and password – via Trial Manager • If you cannot access the randomisation database – call Trial Manager

  15. RANDOMISATION

  16. randomisation

  17. randomisation

  18. prescription

  19. PHARMACY & DISPENSING Prescription • generated from the web-based randomisation system and completed by the prescribing physician Note: EPA-FFA is a fish oil and allergy to fish oil is part of the exclusion criteria. • It defines which container numbers should be dispensed for the participant. • The container numbers specified will have been delivered to your hospital • Give participant seAFOod bag to carry Trial Medication supplies • participant will receive a total of 8 items (boxes/tubs) • Inform participant to start the trial med next morning and always take with food • Trial med to be stored at room temp at / below 25 deg C

  20. STUDY SCHEDULED VISITS & PROCEDURES Food Frequency Questionnaire (to measure how much omega 3 is consumed from the diet) 2 x 6 ml blood sample Urine sample

  21. STUDY SCHEDULED VISITS & PROCEDURES • V2 phone call (week 2) – AEs, trial meds, con meds (15 min) V3 phone call (week 12)– AEs, trial meds, con meds (15 min)

  22. STUDY SCHEDULED VISITS & PROCEDURES • V4 6 month out-patient visit (week 25)– trial medication return & dispensing , AEs, bloods & urine (1 hr)

  23. STUDY SCHEDULED VISITS & PROCEDURES • V5 phone call (week 38)– AEs, trial meds, con meds (15 min) +/- V5a phone call (week 38)– AEs, trial meds, con meds (15 min)

  24. STUDYFLOW DIAGRAM

  25. STUDY SCHEDULED VISITS & PROCEDURES • V6 exit colonoscopy (week 50 or up to 62)–trial med return, AEs, bloods & urine, rectal biopsies (1.5hr)

  26. STUDY SCHEDULED VISITS & PROCEDURES • V7 final visit (week 52 or up to 64) - adenoma details and FFQ ( 25 min) NB see protocol and CRF for time window allowances for each visit

  27. BIOLOGICAL SAMPLES – why? • To understand how EPA and aspirin work, alone and in combination • To identify a biomarker(s) that predicts whether EPA and/or aspirin works (towards personalised chemoprevention) • To determine whether the patient genotype predicts efficacy of EPA and aspirin, alone or in combination

  28. Liquid chromatography- tandem mass spectrometry

  29. BIOLOGICAL SAMPLES - blood • Blood (3 times – start, middle, end) • Blood handling • Centrifuge (own lab or supplied equipment) • Plasma (to measure lipid biomarkers) • White blood cells (to obtain DNA) • Red blood cells (to measure EPA levels) • Lipids are labile so rapid cooling and freezing is preferred

  30. BIOLOGICAL SAMPLES - URINE • Urine (3 times – start, middle, end) Measuring lipid metabolites including stable PGE2 metabolite

  31. BIOLOGICAL SAMPLES – RECTAL BX • Rectal biopsies (exit colonoscopy only) • Fixed adenoma tissue blocks (at end of trial) Rectal biopsies – measuring: 1) EPA incorporation 2) Mucosal lipid levels eg. PGE2, lipoxins, RvE1 Immunhistochemistry for: 1) COX-2 2) Cell receptors for eg. RvE1 (ChemR23)

  32. BIOLOGICAL SAMPLES • LAB MANUAL • Instructions on processing and storage • 30 mins from obtaining samples to freezer (allowing for site-specific factors) • Unique id labels in Investigator Site File section 7 • Collection of samples every 3-4 months by CitySprint courier • Samples long term storage in Bradford lCT (Institute of Cancer Therapeutics) • CONSUMABLES PROVIDED • Blood tubes, aliquots, cryo rack, marker pen, Pathoseal bags, gloves • 1st shipment to supply 10 participants

  33. ADVERSE EVENT REPORTING • Always ask participant about Adverse Events at every phone call and clinic visit • Record all on the AE log and update log at every phone call and clinic visit • If AE fulfils SERIOUS criteria, complete SAE form immediately: • Participant has died from the event • Event is life-threatening if no immediate treatment given • Event has prolonged an existing hospital admission or resulted in a new hospital admission • Event has resulted in persistent or significant disability/incapacity • Event has resulted in a congenital anomaly or a birth defect (following either parent taking trial medication) • Medical or surgical intervention required to prevent one of the outcomes above • Medically significant – does not fulfil any of the criteria above but in the opinion of PI, requires reporting

  34. ADVERSE EVENT REPORTING • PI or delegate must complete SAE form immediately • PI MUST SIGN and complete PI sections • if PI unavailable for next 24 hrs, complete as much as possible and call Trial Manager • Call Trial Manager to notify of an SAE • Fax completed SAE form as soon as completed (within 24 hrs of notification of SAE) • NB enquire specifically about dyspepsia, nausea, abdominal pain,halitosis, diarrhoea, bleeding episodes (including haematemesis/melaena) and diagnosis of stroke at each follow-up visit and telephone call • For the purpose of this Trial pre-planned elective hospital submissions will not be classed as a SAE.

  35. prohibited medications • PROHIBITED MEDS • Warfarin or any other anti-coagulant or anti-platelet therapy (any dose), • Regular (>3x per week on an ongoing basis) prescribed or OTC aspirin, • Regular (>3x per week on an ongoing basis) prescribed or OTC non-steroidal anti-inflammatory drug (NSAID), • Ongoing or planned use of fish oil supplements • Methotrexate use at a weekly dose of 15 mg or more. • NB: 1) Participants should be advised to avoid taking any aspirin-containing over-the-counter • analgesia and to take an alternative (such as paracetamol) when pain relief is • necessary. • 2) “regular” = use on a continuing basis over a period of time in consecutive weeks

  36. EMERGENCY UNBLINDING • “For the majority of cases, unblinding will not be required because there is no antidote to the investigational treatments, and the medical care and usually the management of the patient would not be any different even if the treatment group assignment of the patient were known.” PROTOCOL EMERGENCY ONLY: Local hospital Pharmacy to unblind using unblinding web-based system https://ctu4.nottingham.ac.uk/0921_unblind/login.asp If need arises for non-emergency unblinding then must be discussed with the CI

  37. Withdrawal of participants • Participants can only be withdrawn from the trial completely if : • Participant withdraws consent • Participant lost to follow-up • Participant had more than 1 repeat colorectal endoscopy • Investigator’s opinion due to an Adverse Event Participants who stop trial medication will still be followed- up until end of trial Participants who are unblinded to their treatment allocation will stop the trial medication but will still be followed up until the end of the trial AN END OF TRIAL CRF SHOULD ALWAYS BE COMPLETED

  38. Trial medication side effects ? • Main side effects are: • diarrhoea, nausea, dyspepsia, abdominal pain • 1) Always check participant taking trial medication with food • 2) Trial med can be reduced if AEs causing participants distress • Capsules can be reduced to 1 capsule BD (increase after 1 -2 weeks) • Aspirin can only be stopped not modified

  39. Adverse Events? • Has participant had any of the following persistent symptoms which has lead to consideration of stopping IMP? • nausea • abdo pain/dyspepsia • diarrhoea What number of capsules is participant taking? Are capsules and tablets taken with food? TWO twice a day Flow chart of EPA/placebo capsule reduction NO YES NO YES Give advice about taking IMP with meals Continue to take TWO capsules twice a day ONE twice a day YES What number of capsules is participant taking? TWO twice a day ONE twice a day Increase back to TWO twice a day with food (see note below) Consider stopping capsules but continue tablets and call Trial Manager Reduce to ONE twice a day until next visit/call No capsules Telephone check up within 2 weeks Consider stopping tablets and call Trial Manager Note:- participant should only be encouraged to increase back to TWO capsules twice a day on ONE occasion during the trial. If a participant has increased the number of capsules with return of symptoms then he/she should remain on ONE capsule twice a day

  40. Investigator site file • Each Site will be provided today with a: • Site file • Pharmacy File (remains in pharmacy) • The Site File Contains all trial records kept at the site: • Protocol, Summary of Product Characteristics (SmPC), IMPD, IB • REC approved study documents • Main REC & local R&D approval • MHRA approval • Delegation of Responsibility Log • Signed consent forms • Subject ID / Screening logs • Adverse Event Reporting • Investigator/study personnel CVs and GCP certificates • Investigator Meeting & Initiation Visit Reports • Trial Report • Monitoring Records • It is the Sites responsibility to maintain the ISF

  41. Study management CENTRE expectations • Each BCSP Centre has a target of recruiting a total of 60 participants over 2 yrs • can be divided between the separate sites within the BCSP • If poor recruitment within 6 months - ? Close site and open a new site • All personnel who will be working on seAFOod need to have a GCP certificate and have been trained either at this SIV or by PI/SSP • All patients who are classified as “high-risk” must be entered onto the screening log regardless of whether they are eligible or not. • Crucial for reports and trial management that this data is captured • Screening logs to be faxed through to Ellie every 2 weeks (wednesdays) • reminders will be sent • All personnel need to be recorded on the delegation log with their duties recorded • A copy of this must be sent to CTU and hospital pharmacy every time there is an alteration

  42. Study management expectations • All CRFs to be posted to the Clinical Trials Unit within 1 week of completion • All data captured within the CRF must also be noted either on the BCSP database or within the patient’s medical records • Participant’s medical records must have an entry to say that consent has been given for entry to seAFOod trial • Any invoices for participant travel expenses (up to £10 – must have receipts) or admin costs be submitted to myself CTU with receipts

  43. PROGRESS TO DATE (1) • BCSP CENTRES ALREADY OPENED TO RECRUITMENT: • 14 CENTRES • TEES SC • NORTH OF TYNE SC • SOUTH OF TYNE SC • DERBYSHIRE SC • NORWICH SC • CALDERDALE, KIRKLEES AND WAKEFIELD SC • COUNTY DURHAM AND DARLINGTON SC • HARROGATE, LEEDS AND YORK SC • BRADFORD AND AIREDALE SC • HULL SC • CUMBRIA AND WESTMORELAND SC • NOTTINGHAM SC • LEICS, NORTHANTS AND RUTLAND SC • COVENTY AND WARWICKSHIRE SC • DORSET SC

  44. PROGRESS TO DATE (2) We need YOU! • STUDY RECRUITMENT START DATE: • Recruitment open Nov 2011 • Currently recruited 52 participants • Leading recruiting site = Glenfield and Kettering • Total 853 participants required • 2 year recruitment period

  45. PROGRESS TO DATE (3) • BCSP CENTRES TO BE OPENED TO RECRUITMENT SHORTLY: • 14 CENTRES • SURREY SC • WEST HERTS SC • EAST AND NORTH HERTS SC • CORNWALL SC • SOUTH DEVON SC • BRISTOL AND WESTON SC • SOMERSET SC • SOUTH EAST LONDON SC • WOLVERHAMPTON SC • LANCASHIRE SC • PETERBOROUGH AND HUNTINGDON SC • UNIVERSITY COLLEGE HOSPITAL LONDON SC • SOUTH ESSEX SC • NORTH ESSEX SC • BOLTON SC

  46. Progress to date (4)

  47. SEAFOOD WEBSITE

More Related